Carrie Powell, NP
Nurse Practitioner · Great Falls, MTNPI 1093812265
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Amgen at 39.3% of the total. Reporting peaked in 2024 at $624 and has fallen 68.0% since, to $199 in 2025. Among nurse practitioner clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $29.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$612
- AstraZeneca$237
- Novo Nordisk$160
- Lilly USA, LLC$116
- AbbVie$107
- GSK$60
- plus $267 from 12 others
What the payments were for
- Food & beverage$1,558100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $612 |
| AstraZeneca | 8 | $237 |
| Novo Nordisk | 3 | $160 |
| Lilly USA, LLC | 4 | $116 |
| AbbVie | 5 | $107 |
| GSK | 3 | $60 |
| Mallinckrodt Hospital Products Inc. | 1 | $46 |
| Astellas Pharma US Inc | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Bayer | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Novartis | 1 | $13 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,558 in reported general payments places this provider in the 90th percentile of 357 nurse practitioner providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $37,807 |
| EliquisApixaban | 12 | $17,308 |
| TrulicityDulaglutide | 13 | $12,195 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $4,132 |
| Atorvastatin Calcium | 191 | $1,659 |
| Levothyroxine Sodium | 151 | $1,572 |
| Potassium Chloride | 37 | $1,313 |
| Lisinopril | 93 | $1,186 |
| Omeprazole | 105 | $1,104 |
| Losartan Potassium | 103 | $1,038 |
| Gabapentin | 69 | $875 |
| Rosuvastatin Calcium | 42 | $824 |
| Duloxetine Hcl | 51 | $808 |
| Sertraline Hcl | 75 | $802 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $160 | $37,80737 claims |
| PfizerEliquis | $14 | $17,30812 claims |
| Lilly USA, LLCTrulicity | $116 | $12,19513 claims |
| AbbVieSynthroid | $107 | $32817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 357 nurse practitioner providers in Montana.
Other nurse practitioner in Great Falls
- Bowen TrystiansonGreat Falls$6K
- Amber MolnarGreat Falls$4K
- Jessica BosoGreat Falls$4K
- Whitney McKinleyGreat Falls$3K
- Elizabeth O'ConnorGreat Falls$3K
- Vilma HerreraGreat Falls$2K
- Martin CamachoGreat Falls$1K
- Gina HansenGreat Falls$1K
- Khi SoldanoGreat Falls$951
- Melanie BrownGreat Falls$833
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.